Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 79

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 79
---
ii) patents licensed to us where we or an affiliate have the financial responsibility 
 to bring such infringement actions pursuant to the relevant license agreement;                                                                     |

| • | we will develop technologies or product candidates which are patentable, either alone or in conjunction 
 with third parties;                                                                                     |

| • | the ownership, scope or validity of any patents registered in our name (either solely or jointly) from                                  
 time to time will not be challenged by third parties, including parties with whom we, or any affiliate, have entered into collaboration 
 projects or co-ownership arrangements and that any such challenge will not be successful;                                               |

| 39 |

| • | any patent or patent application owned solely or jointly by us will not be challenged on grounds that                                         
 we failed to identify the correct inventors or that we failed to comply with our duty of disclosure to the United States Patent and Trademark 
 Office or any equivalent office in a foreign jurisdiction having a disclosure requirement;                                                    |

| • | any issued patent in our sole or joint name from time to time will not be challenged in one or more post-grant                    
 proceedings, including but not limited to inter partes review, derivation proceedings, interferences, and that like; and that any 
 such challenge will not result in a complete or partial loss of rights to such issued patent or patents;                          |

| • | any patent applications in our sole or joint name from time to time will not be opposed by any third party,            
 including parties to collaboration, co-existence and any other contractual relationship with us or any of its members; |

| • | the license agreements between us and third parties are and will be valid and subsisting in the future                
 or until their expiry dates, and that we have complied with our contractual obligations under the license agreements; |

| • | all intellectual property capable of being commercialized that is or has been generated pursuant to collaboration 
 agreements between us and third parties will be or has been identified;                                           |

| • | all intellectual property generated pursuant to collaboration agreements and to which we have a contractual          
 entitlement or generated by employees has been lawfully assigned into our sole name (or to one of our subsidiaries); |

| • | in respect of all intellectual property generated pursuant to a collaboration agreement between us and                                 
 a third party to which we and that third party have a joint contractual entitlement, that such intellectual property has been lawfully 
 assigned into joint names and the rights between us and that third party are properly regulated by a co-ownership agreement; and